Bioton looks for cash injection from private investors

The company will sell 10% of its shares, out of which roughly 40% will be sold to financial investors, while the remainder will go to individuals. Bioton intends to sell its shares mostly to domestic investors and plans to encourage them with an ambitious investment program and growth perspectives. "We are the only domestic company manufacturing human insulin. The market on which we operate is very promising (by 2006 its value will increase to zł.5.4 billion from zł.3.7 billion in 2001). We also intend to operate globally," said Adam Wilczęga, president of Bioton. The company's investment program will cost almost zł.250 million by 2009. (Puls Biznesu, pp. 1, 10) M.M.